Back to Main

Faculty Detail    
Name QIANA L MATTHEWS
Assistant Professor of Medicine		  
Campus Address BBRB 206 Zip 2170
Phone  (205) 934-1632
E-mail  qlm@uab.edu
Other websites Medicine/ Infectious Diseases
     


Faculty Appointment(s)
Appointment Type Department Division Rank
Primary  Med - Infectious Diseases  Med - Infectious Diseases Assistant Professor Adjunct
Secondary  Microbiology  Microbiology Assistant Professor Adjunct

Biographical Sketch 
Dr. Qiana L. Matthews completed her undergraduate studies in Biology at Clark Atlanta University in 1999. She obtained her PhD in 2003 from Meharry Medical College, Nashville TN (USA). Dr. Matthews went on to complete a postdoctoral fellowship in the Division of Human Gene Therapy, at the University of Alabama at Birmingham (UAB), (2003-2008). Currently, Dr. Matthews is working as a molecular virologist. She is working with adenoviral vectors for gene therapy, virotherapy, and vaccine applications. Dr. Matthews is an Associate Scientist in the Center for AIDS Research as well as an Assistant Professor in the Department of Medicine/Division of Infectious Diseases.



Research/Clinical Interest
Title
Next generation adenoviruses for improved vaccines and therapies
Description
Our main research area concentrates on developing a safe and effective HIV vaccine using human adenovirus (Ad)-based delivery strategies. In this regard, we focus on modifying adenovirus vectors to exhibit less (Ad5) vector immunogenicity, while focusing the immune response to HIV antigens by means of a novel chimeric Ad vector platform, antigen presentation, and immune activation platform. Our other interest in the laboratory include: (i) developing gene therapy models that will contribute to the advancement of biomedical sciences and human health. (ii) developing safe and effective vaccines for other infectious diseases. (iii) developing novel approaches to treat and HIV-associated malignancies. (iv) developing novel approaches to treat Uterine Leiomyoma.

Selected Publications 
Publication PUBMEDID
Stoff-Khalili MA, Rivera AA, Stoff A, Michael Mathis J, Rocconi RP, Matthews QL, Numnum MT, Herrmann I, Dall P, Eckhoff DE, Douglas JT, Siegal GP, Zhu ZB, Curiel DT. Combining high selectivity of replication via CXCR4 promoter with fiber chimerism for effective adenoviral oncolysis in breast cancer. Int J Cancer. 2007 Feb 15;120(4):935-41.





 		 17131341 
Matthews QL, Sibley DA, Wu H, Li J, Stoff-Khalili MA, Waehler R, Mathis JM, Curiel DT. Genetic incorporation of a herpes simplex virus type 1 thymidiMol Imaging. 2006 Oct-Dec;5(4):510-9.
 		 17150163 
Matthews QL, Curiel DT. Gene therapy: human germline genetic modifications--assessing the scientific, socioethical, and religious issues. South Med J. 2007 Jan;100(1):98-100.

 		 17269544 
Tang Y, Le LP, Matthews QL, Han T, Wu H, Curiel DT. Derivation of a triple mosaic adenovirus based on modification of the minor capsid protein IX. Virology. 2008 Aug 1;377(2):391-400.
 		 18570971 
Matthews QL, Yang P, Wu Q, Belousova N, Rivera AA, Stoff-Khalili MA, Waehler R, Hsu HC, Li Z, Li J, Mountz JD, Wu H, Curiel DT. Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach. Virol J. 2008 Aug 21;5:98.  18718011 
Thacker EE, Timares L, Matthews QL. Strategies to overcome host immunity to adenovirus vectors in vaccine development. Expert Rev Vaccines. 2009 Jun;8(6):761-77.

 		 19485756 
Tang Y, Wu H, Ugai H, Matthews QL, Curiel DT. Derivation of a triple mosaic adenovirus for cancer gene therapy. PLoS One. 2009 Dec 31;4(12).

 		 20046872 
Li J, Fatima A, Komarova S, Ugai H, Uprety P, Roth JC, Wang M, Oster RA, Curiel DT, Matthews QL. Evaluation of adenovirus capsid labeling versus transgene expression. Virol J. 2010 Jan 26;7:21.

 		 20102632 
Matthews QL, Fatima A, Tang Y, Perry BA, Tsuruta Y, Komarova S, Timares L, Zhao C, Makarova N, Borovjagin AV, Stewart PL, Wu H, Blackwell JL, Curiel DT. HIV antigen incorporation within adenovirus hexon hypervariable 2 for a novel HIV vaccine approach. PLoS One. 2010 Jul 27;5(7):e11815  20676400 
Matthews QL. Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach.
Mol Pharm. 2011 Feb 7;8(1):3-11. 		 21047139 
Gamble LJ, Matthews QL. Current progress in the development of a prophylactic vaccine for HIV-1. Drug Des Devel Ther. 2010 Dec 22;5:9-26.

 		 21267356 
Gamble LJ, Borovjagin AV, Matthews QL. Role of RGD-containing ligands in targeting cellular integrins: Applications for ovarian cancer virotherapy (Review).
Exp Ther Med. 2010 Mar;1(2):233-240.
 		 21494315 
Liu RM, Vayalil PK, Ballinger C, Dickinson DA, Huang WT, Wang S, Kavanagh TJ, Matthews QL, Postlethwait EM.Transforming growth factor beta suppresses glutamate-cysteine ligase gene expression and induces oxidative stress in a lung fibrosis model.Free Radic Biol Med. 2012 Aug 1;53(3):554-63.
 		 22634145 
Bone RN, Icyuz M, Zhang Y, Zhang Y, Cui W, Wang H, Peng JB, Matthews QL, Siegal GP, Wu H.
Gene transfer of active Akt1 by an infectivity-enhanced adenovirus impacts& b-cell survival and proliferation differentially in vitro and in vivo. Islets. 2012 Nov 1;4(6).  		 23183538 
 

Keywords
vaccines, HIV, adenovirus, gene therapy